Minerva Biotechnologies, a private company, is in the field of stem cells and cancer stem cells, and discovered that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star), according to the company’s website (see here: www.MinervaBio.com). In this SNNLive On-Location, our host spoke with Cynthia Bamdad, Ph.D., CEO of Minerva Biotechnologies Corporation, a private company, in New York City, NY.
In this video interview, Dr. Bamdad and our host discuss the following topics:
- Overview of Minerva Biotechnologies Corporation
- Discusses the company’s science and how it applies to medicine
- Focus on solid tumor cancer
- Dr. Bamdad’s background